Clinical Research Directory
Browse clinical research sites, groups, and studies.
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
Sponsor: Riccardo Guglielmo
Summary
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.
Official title: ESKPSY: Esketamine in Real-World Settings: Clinical Outcomes, Predictors of Response, Life Functioning and Biological Pathways
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2022-11-01
Completion Date
2030-08
Last Updated
2026-03-31
Healthy Volunteers
No
Conditions
Interventions
Esketamine (Intranasal Spray)
Esketamine Intranasal Spray at a dosage ranging from 28 to 84 mg weekly, with twice-weekly administration during the first month of treatment, according to the approved labeling
Locations (5)
Ospedale Policlinico San Martino
Genova, Ge, Italy
Csm Dds 8
Genova, Ge, Italy
Università di Chieti
Chieti, Italy
ASST Fatebenefratelli Sacco
Milan, Italy
ASST Pavia
Pavia, Italy